Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients.

Borges S, Desta Z, Jin Y, Faouzi A, Robarge JD, Philips S, Nguyen A, Stearns V, Hayes D, Rae JM, Skaar TC, Flockhart DA, Li L.

J Clin Pharmacol. 2010 Apr;50(4):450-8. doi: 10.1177/0091270009359182. Epub 2010 Jan 15. Erratum in: J Clin Pharmacol. 2010 Jun;50(6):725. Philip, Santosh [corrected to Philips, Sanosh].

2.

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.

Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA.

Clin Pharmacol Ther. 2006 Jul;80(1):61-74.

3.

Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.

Antunes MV, Linden R, Santos TV, Wallemacq P, Haufroid V, Classen JF, Andreolla H, Costa N, Fontanive TO, Rosa DD.

Ther Drug Monit. 2012 Aug;34(4):422-31. doi: 10.1097/FTD.0b013e318260b46e.

PMID:
22777153
4.

The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.

Opdam FL, Dezentje VO, den Hartigh J, Modak AS, Vree R, Batman E, Smorenburg CH, Nortier JW, Gelderblom H, Guchelaar HJ.

Cancer Chemother Pharmacol. 2013 Mar;71(3):593-601. doi: 10.1007/s00280-012-2034-4. Epub 2012 Dec 11. Erratum in: Cancer Chemother Pharmacol. 2013 Mar;71(3):603.

PMID:
23228987
5.

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA.

J Natl Cancer Inst. 2005 Jan 5;97(1):30-9.

PMID:
15632378
6.

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.

Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN.

Breast Cancer Res Treat. 2007 Jan;101(1):113-21. Epub 2006 Nov 18.

PMID:
17115111
7.

CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.

Teft WA, Gong IY, Dingle B, Potvin K, Younus J, Vandenberg TA, Brackstone M, Perera FE, Choi YH, Zou G, Legan RM, Tirona RG, Kim RB.

Breast Cancer Res Treat. 2013 May;139(1):95-105. doi: 10.1007/s10549-013-2511-4. Epub 2013 Apr 12. Erratum in: Breast Cancer Res Treat. 2013 Nov;142(1):225.

PMID:
23580071
8.

Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.

Damodaran SE, Pradhan SC, Umamaheswaran G, Kadambari D, Reddy KS, Adithan C.

Cancer Chemother Pharmacol. 2012 Jul;70(1):75-81. doi: 10.1007/s00280-012-1891-1. Epub 2012 May 24.

PMID:
22623212
9.

Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.

Dezentjé VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk-Sukel MP, Casparie MK, Egberts AC, Nortier JW, Guchelaar HJ.

J Clin Oncol. 2010 May 10;28(14):2423-9. doi: 10.1200/JCO.2009.25.0894. Epub 2010 Apr 12.

PMID:
20385997
10.

Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score.

Wu AH, Lorizio W, Tchu S, Lynch K, Gerona R, Ji W, Ruan W, Ruddy KJ, Desantis SD, Burstein HJ, Ziv E.

Breast Cancer Res Treat. 2012 Jun;133(2):677-83. doi: 10.1007/s10549-012-1963-2.

PMID:
22294487
11.

The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity.

Welzen ME, Dezentjé VO, van Schaik RH, Colbers AP, Guchelaar HJ, van Erp NP, den Hartigh J, Burger DM, van Laarhoven HW.

Ther Drug Monit. 2015 Aug;37(4):501-7. doi: 10.1097/FTD.0000000000000195.

PMID:
26192892
12.

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.

Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, Purdie CA, Jordan LB, Ferraldeschi R, Latif A, Hadfield KD, Clarke RB, Ashcroft L, Evans DG, Howell A, Nikoloff M, Lawrence J, Newman WG.

Breast Cancer Res Treat. 2011 Jan;125(1):279-87. doi: 10.1007/s10549-010-1139-x. Epub 2010 Sep 1.

PMID:
20809362
13.

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA.

J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64.

PMID:
14652237
14.

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.

Dezentjé VO, Opdam FL, Gelderblom H, Hartigh den J, Van der Straaten T, Vree R, Maartense E, Smorenburg CH, Putter H, Dieudonné AS, Neven P, Van de Velde CJ, Nortier JW, Guchelaar HJ.

Breast Cancer Res Treat. 2015 Oct;153(3):583-90. doi: 10.1007/s10549-015-3562-5. Epub 2015 Sep 14.

15.

The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.

Bijl MJ, van Schaik RH, Lammers LA, Hofman A, Vulto AG, van Gelder T, Stricker BH, Visser LE.

Breast Cancer Res Treat. 2009 Nov;118(1):125-30. doi: 10.1007/s10549-008-0272-2. Epub 2009 Feb 3.

PMID:
19189212
16.

Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.

Binkhorst L, Mathijssen RH, Jager A, van Gelder T.

Cancer Treat Rev. 2015 Mar;41(3):289-99. doi: 10.1016/j.ctrv.2015.01.002. Epub 2015 Jan 14. Review.

PMID:
25618289
17.

No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.

Markkula A, Hjertberg M, Rose C, Ingvar C, Jernström H.

Acta Oncol. 2014 Feb;53(2):195-200. doi: 10.3109/0284186X.2013.840739. Epub 2013 Oct 14.

PMID:
24125101
18.

Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.

Goetz MP, Kamal A, Ames MM.

Clin Pharmacol Ther. 2008 Jan;83(1):160-6. Epub 2007 Sep 19. Review.

19.

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.

Ruddy KJ, Desantis SD, Gelman RS, Wu AH, Punglia RS, Mayer EL, Tolaney SM, Winer EP, Partridge AH, Burstein HJ.

Breast Cancer Res Treat. 2013 Oct;141(3):421-7. doi: 10.1007/s10549-013-2700-1. Epub 2013 Sep 24.

PMID:
24062210
20.

Personalized tamoxifen: a step closer but miles to go.

Bardia A, Stearns V.

Clin Cancer Res. 2010 Sep 1;16(17):4308-10. doi: 10.1158/1078-0432.CCR-10-1506. Epub 2010 Jul 22.

Supplemental Content

Support Center